10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Recombinant Human EGF-L7
Catalog # PBG10073

Specification

Recombinant Human EGF-L7 - Product Information

Recombinant Human EGF-L7 - Additional Information

Description
EGF-L7 (Epidermal Growth Factor Like Protein 7, Multiple EGF Like Domains Protein 7, VE Statin) is a multi-domain protein containing two EGF like domains and one EMI domain. It is expressed almost exclusively in endothelial cells and functions to promote normal development of the vascular system, particularly tubulogenesis. EGF-L7 is capable of antagonistic binding to Notch receptors resulting in the inhibition of Notch signaling in HUVEC and neural stem cells. In research models inducing hypoxia and subsequent reoxygenation, (H/R), EGF-L7 can inhibit ICAM-1 expression and enhance the inhibition of NF-kappaB activation. Additionally, EGF-L7 can chemoattract endothelial cells and bind to the extracellular matrix. The overexpression of EGF-L7 is observed in various cancers, and is generally correlated with increased metastasis and a poor prognosis. Recombinant human EGF-L7 is a 28 kDa protein containing 251 amino acid residues.

BiologicalActivity
Data Not Available.

Authenticity
Verified by N-terminal and Mass Spectrometry analyses (when applicable).

Endotoxin
Endotoxin level is <0.1 ng/ µg of protein (<1EU/ µg).

Protein Content
Verified by UV Spectroscopy and/or SDS-PAGE gel.

Storage
-20°C

Precautions
Recombinant Human EGF-L7 is for research use only and not for use in diagnostic or therapeutic procedures.

Recombinant Human EGF-L7 - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence

- Immunoprecipitation
- Flow Cytomety
- Cell Culture

Recombinant Human EGF-L7 - Images